CN1382476A - Application of yellowstem milkwort in preparing medicines - Google Patents

Application of yellowstem milkwort in preparing medicines Download PDF

Info

Publication number
CN1382476A
CN1382476A CN 02112749 CN02112749A CN1382476A CN 1382476 A CN1382476 A CN 1382476A CN 02112749 CN02112749 CN 02112749 CN 02112749 A CN02112749 A CN 02112749A CN 1382476 A CN1382476 A CN 1382476A
Authority
CN
China
Prior art keywords
radix polygalae
polygalae fallacis
application
pad
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 02112749
Other languages
Chinese (zh)
Other versions
CN1209127C (en
Inventor
朱丹妮
寇俊萍
马仁强
严永清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to CN 02112749 priority Critical patent/CN1209127C/en
Publication of CN1382476A publication Critical patent/CN1382476A/en
Application granted granted Critical
Publication of CN1209127C publication Critical patent/CN1209127C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An application of the yellowsteam milkwort as Chinese-medicinal materials in prepairng the medicines to treat Meniere's disease is disclosed. Its decoction or water-soluble component has also the function of promoting blood circulation and improving immunity.

Description

The application of Chinese medicine Radix Polygalae fallacis in pharmacy
Invention field
The present invention relates to the medical usage of Chinese medicine Radix Polygalae fallacis, is the purposes of Chinese medicine Radix Polygalae fallacis in preparation treatment Meniere medicine specifically.
Background of invention
Radix Polygalae fallacis is Polygalaceae polygala (Polygala aureocauda Dunm), below be called for short PAD for sake of convenience, be precious jade doctor common drug, have another name called " knot end room ", " Hemerocallis citrina Baroni ginseng ", " kwan-yin string ", " the young tree of chicken ", " DIAOHUANG ", " hanging the water lotus ", " Hemerocallis citrina Baroni hangs the water lotus " etc.It is documented that Radix Polygalae fallacis has benefiting vital QI and blood, invigorating spleen to remove dampness, promoting blood flow to regulate menstruation, effects such as treatment acute, chronic hepatitis and nutritional edema, (referring to " Chinese medicine voluminous dictionary ", the new medical college in Jiangsu is compiled, Shanghai science tech publishing house, in June, 1988 front page, 2079).
Over past ten years, domestic research to Radix Polygalae fallacis mainly concentrates Radix Polygalae fallacis to aspects such as animal cardiac muscle function, the oxidations of lipotropism matter, and polysaccharide extraction and anti-stress thereof, antiviral research.Referring to: the yellow light etc. that wins, the 30 routine clinical observations of Radix Polygalae fallacis treatment hyperlipemia, Hunan Journal of Traditional Chinese Medicine, 1999,15 (3): 6-7; Qin Huazhen etc., the extraction of Radix Polygalae fallacis polysaccharide and toxicologic study, basic unit's Chinese medicine magazine, 1998,12 (2): 51; Fan Xiuzhen, the mensuration of Radix Polygalae fallacis oral liquid anti-peroxidation lipid, Chinese medicine research, 1998,14 (2): 35-36; Qin Huazhen etc., the anti-stress effect of Radix Polygalae fallacis polysaccharide, Guangxi Chinese medicine, 1996,19 (3): 52-54; Guo Jiansheng, Radix Polygalae fallacis be to the influence of laboratory animal myocardial function, Hunan College of Traditional Chinese Medicine's journal, 1992,19 (3): 40-43.
Present clinical with tea benzene Lamine treatment Meniere, but tea benzene Lamine is mainly used in the nausea and vomiting that motion sickness causes, improves dizzy symptom, and the basic pathology and the auditory dysesthesia of Meniere are not seen influence.In addition, tea benzene Lamine also has H 1Some side effect of receptor blocking agent are as drowsiness, xerostomia etc.
Summary of the invention
The technical problem to be solved in the present invention is how to prepare the purposes for the treatment of in the Meniere medicine with medical usage, especially Radix Polygalae fallacis by modern pharmacology experimentation Chinese medicine Radix Polygalae fallacis.
The present invention need be by the pharmacological evaluation of Radix Polygalae fallacis, development not only can improve the dizzy symptom of animal, and also have blood circulation promoting and blood stasis dispelling, immunosuppressive action, and can improve the auditory dysesthesia that experimental hydrolabyrinth causes, thus more effectively prevent and treat Meniere.Simultaneously, there is not H 1The side effect of receptor blocking agent is as drowsiness, xerostomia etc.
The present invention also needs to solve the effective site of Radix Polygalae fallacis in preparation treatment Meniere medicine.
Technical scheme of the present invention is as follows:
The application of Radix Polygalae fallacis in preparation treatment Meniere medicine.
Especially use the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis, preparation treatment Meniere medicine.
The decocting liquid or the water soluble ingredient of Radix Polygalae fallacis can mix with conventional pharmaceutic adjuvant, make the various dosage forms that are fit to clinical usefulness.
The present invention also comprises the application of Radix Polygalae fallacis in the preparation activating blood and removing stasis drug.It is characterized in that: the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis, can mix with pharmaceutic adjuvant.
The present invention also comprises the application of Radix Polygalae fallacis in the preparation immune drug.It is characterized in that: the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis, can mix with pharmaceutic adjuvant.
The present invention also comprises the application of Radix Polygalae fallacis in the preparation anti-inflammatory drug.
The decocting liquid of Radix Polygalae fallacis can mix with conventional pharmaceutic adjuvant, makes various dosage forms.Can mix with the adjuvant hydroxypropyl cellulose, make capsule routinely.Can mix with dextrin, Icing Sugar, make granule routinely.Can mix with starch, dextrin, make tablet routinely.Can adopt alcohol deposition method, make oral liquid routinely.Can adopt resin adsorption method, make sugar-free medicinal granules routinely.
The decocting liquid of Radix Polygalae fallacis can use column chromatography the water outlet soluble components, mainly is Saponin class and polysaccharide component.The water-soluble component that separation is obtained mixes with conventional pharmaceutic adjuvant, can be made into various dosage forms.Can mix with microcrystalline Cellulose, make capsule routinely.Can mix with dextrin, Icing Sugar, make granule routinely.Can mix with starch, dextrin, make tablet routinely.
According to the central dogma of Meniere, various paathogenic factors at first cause hydrolabyrinth (HL), and on this pathologic basis, produce corresponding symptom (referring to: delayed release Shandong, Wang Zhengmin.Meniere and endolymphatic environment are unbalance, foreign medical science otolaryngology fascicle, 1997,21 (4): 1998; Han Jiju, Zhang Suzhen, internal ear lymph fluid pressure and to the influence of inner ear function, foreign medical science otolaryngology fascicle, 1996,20 (4): 193).Endolymphatic generation is too much, and backflow or malabsorption all can cause hydrolabyrinth, but this process is a slow process, just sees auditory dysesthesia after hydrops acquires a certain degree.Endolymph fluid mainly is absorbed at endolymphatic sac, and operation destroys endolymphatic sac, can make normal guinea pig cause the endolymph malabsorption and causes hydrolabyrinth.Operation back 50d carries out hearing test, the CAP threshold value of finding model group is apparently higher than sham operated rats, significantly be longer than sham operated rats incubation period, the CAP amplitude also significantly reduces, obvious hearing impairment appears in the hints model animal, PAD has remarkable reduction effect to the CAP threshold value, and shortens its incubation period, and prompting has the obvious audition effect that improves to Cavia porcellus hydrolabyrinth model.Experimental results show that: it is dizzy that PAD both can have been alleviated the cardinal symptom of MD, also can improve hearing impairment due to the wherein main pathology changing film hydrolabyrinth, can be prepared into the medicine of clinical prevention MD.Clinical use PAD dosage: 3 times/day, 1 gram/time (PAD make a living dose 20%).
The present invention designs two animal models according to the symptom and the pathological change of Meniere (being designated hereinafter simply as MD), observes the pharmacological action of Radix Polygalae fallacis (being designated hereinafter simply as PAD).The dizzy experimental result of rabbit shows due to the sinusoidal wave rotation: PAD3g/kg is extremely significantly inhibitory action to the slow phase angular velocity of nystagmus, and can suppress the nystagmus persistent period; Average nystagmus frequency there is not obvious influence.Hydrolabyrinth (HL) model experiment result shows due to the operation destruction Cavia porcellus endolymphatic sac (ES): PAD5g/kg treatment administration can significantly reduce acoustic nerve complex potential (CAP) threshold value in 20 days, shorten its incubation period, The above results prompting PAD has vertigo, improve the effect of hearing impairment due to the hydrolabyrinth, for the clinical MD of being used for control provides the pharmacology foundation.
In addition, Radix Polygalae fallacis (PAD) also has blood circulation promoting and blood stasis dispelling, immunosuppressant and anti-inflammatory activity, these pharmacological actions make Radix Polygalae fallacis not only can prepare blood circulation promoting and blood stasis dispelling, immunosuppressant and anti-inflammatory drug, and its blood circulation promoting and blood stasis dispelling, immune antiinflammatory pharmacological action also have the effect of auxiliary treatment or Synergistic treatment to Meniere.Experiment showed, the PAD3g/kg successive administration eight, and significantly reduced whole blood contrast viscosity and the reduction ratio viscosity of blood stasis rat due to the macromolecule right rotary glycoside, plasma viscosity is had reduction trend; PAD4,2g/kg can extremely significantly expand Mice Auricle arteriole, venule, increases the open number of blood capillary; The continuous ig of PAD4g/kg six days to PC inducing mouse IV allergic induce have mutually extremely remarkable, remarkable inhibitory action, PAD8,4g/kg ig 2 times can be extremely remarkable, significantly suppress above-mentioned mice and attack phase.
The specific embodiment
Embodiment 1
1. material
1.1 medicine and reagent
The preparation of PAD water extract: pulverizing medicinal materials, 10 times of water gagings soaked 12 hours, decoct after 1 hour, 8 times of reuse, 6 times of decoctings boiled 2 times each 1 hour, merged three times filtrate, were concentrated into 1: 1, got PAD water extract, and cold preservation is standby, tests used dosage in crude drug.Tea benzene Lamine (Theohydramine), Nanjing second pharmaceutical factory, lot number: 970501; Pentobarbital sodium (Sodium Pentobarbital), Guangzhou Chemical Reagent Factory (import packing), lot number: 850601.1.2 animal
White rabbit, 2.5-3.0Kg, ♀ ♂ dual-purpose is provided by Nantong Medical College's Experimental Animal Center; Cavia porcellus, 250-300g, ♀ ♂ dual-purpose is provided by new middle new drug research center animal housing of China Medicine University.1.3 instrument
The program control table machine of the attached TP-8 of the electronic swivel chair of JKY-II type, Beijing IAM; RM-800 eight road physiographs, Japanese photoelectricity company; 307-6 table electric dental engine car, apparatus factory of Shanghai tooth section; The T101-64 operating lamp, Chaoyang, Beijing Electronic Instruments Plant; Oneself reequips anatomical lens; F361-81 direct current head amplifier, Shanghai Physiology Inst., Chinese Academy of Sciences produces; The straight less Electronic Instruments Plant of δ s-II type stimulator, Qidong, Jiangsu; Band is analyzed CAP, CM-AD plate 386 computers automatically; Standard testing audition loudspeaker, LC-1KVA efficiently exchange purifying and pressure stabilizing electric current device, and Quanzhou is electronic equipment factory near a river.
2. method and result
2.1 the influence that rabbit is revolved dizzy model nystagmus due to the rotation of offset of sinusoidal ripple
Prepare animal model according to literature method.Referring to: Shao Zhengyi, Ling Xiang, Qian Dongsheng etc. are used for two animal models that anti-dizzy medicine is studied, Chinese Pharmacological circular, 1994; 10 (5): 394; Shao Zhengyi, Ling Xiang, Qian Dongsheng etc., " relieving fainting bolt " be to the pharmacodynamic observation of rabbit vestibular dysfunction, Chinese nautical medicine magazine, 1995; 2 (3): 28.
2.5-3kg white rabbit, each 6 of ♀ ♂ are divided into three groups: matched group ig distilled water, positive controls ig tea benzene Lamine 25mg/kg, experimental group ig PAD3g/kg at random.The rabbit that will regain consciousness places rabbit hutch to cut off two paropias and the head part rabbit hair, expose skin, be positioned over electronic swivel chair, with two 0.5-1.0cm place Intradermal that insert rabbit right and left eyes outer canthus with the acupuncture needle self-made electrode respectively, make leading electrode, the 3rd electrode insert head top Intradermal is as the reference electrode.The nystagmus signal is imported eight road physiology monitors through each electrode, monitors by oscillograph, and traces the nystagmus waveform by recording stylus, muffles the rabbit head, leaves standstill several minutes, treats that baseline steadily starts swivel chair in the back, and peak angular velocity is 60 ° of S -1, frequency 0.25Hz, rotation 5min, waveform when recording start, 3min and 4min30s, each remembers 30s, observes after the stall and the record nystagmus persistent period.Eight road physiology monitor conditions: sensitivity 1mV/DIV, filtering 100Hz, chart drive speed 1cm/s, time constant 2s.1h rabbit nystagmus waveform before the record administration and after the administration, the following index of measurements and calculations: peak period slow phase angular velocity (each measuring point is respectively got the big ripple of 4 amplitudes, totally 12), crest frequency and nystagmus persistent period (after the stall).By the visible PAD of table 1 slow phase angular velocity is had extremely obviously inhibitory action, positive drug has obvious inhibitory action to slow phase angular velocity, and the nystagmus persistent period is obvious inhibitory action, and the two does not have obvious influence to average nystagmus frequency.
What rabbit was revolved dizzy model nystagmus due to the table 1 PAD offset of sinusoidal ripple rotation influences group dosage slow phase angular velocity (μ v/s) average frequency (t/s) persistent period (s)
(g/kg) matched group after the administration before the administration after the administration before the administration after the administration before the administration--27.46 ± 28.81 ± 1.19 ± 1.07 ± 4.32 ± 8.90 ±
5.34 5.32 0.03 0.12 2.41 7.74 tea benzene Lamines 0.025 26.90 ± 20.19 ± 0.95 ± 0.89 ± 11.39 ± 2.63 ±
3.35 2.10* 0.09 0.11 6.78 1.04* PAD 3 29.03± 19.82± 0.99± 0.85± 3.80± 3.00±
4.71 2.59** 0.19 0.37 1.15 1.84 annotates: n=4, X ± SD * P<0.05 * * P<0.01 is with comparison before the administration
2.2 PAD is to the influence of Cavia porcellus operation property hydrolabyrinth
Experiment reference: Wu Zhengda, Ceng Zhaolin, fourth Dalian etc., the active variation of the early stage cochlear potentials of experimental hydrolabyrinth, Chinese hals,Nasen und Ohrenheilkunde magazine, 1993; 28 (1): 28; Tan Changqiang, clock is open-minded, Cao Yincheng etc., the immunity of endolymphatic sac isoantigen causes the experimentation of autoimmunity M é nier é disease, ear,nose ﹠ throat-head and neck surgery, 1993; 28 (3): 47; Zhang Suzhen, Li Xingqi, Shi Yongbing etc., the position auditory function test of experimental hydrolabyrinth, Chinese hals,Nasen und Ohrenheilkunde magazine, 1993; 28 (5): 275.
Select auricle reacting positive Cavia porcellus for use, ip2% pentobarbital sodium 40mg/kg anesthesia, head cropping, iodine disinfection, scalp central authorities make a kerf, muscle are separated with occipital bone until the exoccipital bone ridge from posterior cranial fossa, demonstrate the back atlanto-occipital membrane, Foramen magnum is ground off with dental drill up to the exoccipital bone ridge, separate cerebral dura mater, expose sigmoid sinus, under anatomical lens, push sigmoid sinus to cerebral dura mater gently with the micromesentery probe, push inward gently to a groove along the brain bone, be endolymphatic sac.After destroying the both sides endolymphatic sac respectively, each injects 2 μ l trichloroacetic acid, skin suture.The sham-operation Mus only accomplishes to see till the sigmoid sinus.Get 5 of 10 of back 30 days Cavia porcelluss of operation and sham operated rats, be divided into three groups at random: the equal ig distilled water of sham operated rats and model group, experimental group PAD5g/kg, successive administration 20d observes the therapeutical effect of PAD.Last administration next day, Cavia porcellus ip2% pentobarbital sodium 40mg/kg anesthesia cuts off auricle limit hair, makes a kerf along the auricle root, uses the mosquito forceps separating muscle, exposes nervus facialis, advances about 1mm with self-made electrode inwards along facial canal.With the facial canal electrode is anode, skin of neck is a negative electrode, measure acoustic nerve complex potential (CAP) with Click, select 110dB, 100dB respectively ... ten sound sections of 20dB, the signal of telecommunication is the input computer after pre-amplifier amplifies, and the machine display process is calculated the CAP threshold value as calculated, amplitude, incubation period etc.By table 2 as seen: the Cavia porcellus endolymphatic sac destroyed back 50 days, and the CAP threshold value extremely significantly raises, incubation period utmost point significant prolongation, amplitude significantly reduces, hints model group Cavia porcellus audition obviously descends.The CAP threshold value is raise in PAD5g/kg treatment administration and prolongation of latency all has remarkable inhibitory action, and certain rising CAP amplitude trend is arranged; The prompting PAD Cavia porcellus endolymphatic hydropa model hearing impairment effect that has clear improvement.
Table 2 PAD treatment administration is to the influence of endolymphatic hydropa model Cavia porcellus CAP
CAP amplitude (μ V) CAP incubation period (ms) CAP threshold value group 110dB 100dB 90dB 100dB 100dB 90dB (dB) sham operated rats 133.2 ± 137.9 ± 122.2 ± 2.51 ± 2.60 ± 2.51 ± 48.01 ±
46.2 45.5 28.7 0.23 0.21 0.35 8.16 model group 81.9 ± 79.6 ± 71.4 ± 2.93 ± 2.98 ± 3.23 ± 82.51 ±
40.1 # 35.7 # 26.4 ## 0.25 ## 0.29 ## 0.16 ## 7.08 ##PAD 99.7± 107.1± 90.5± 2.69± 2.74± 2.79± 53.33±
40.6 42.3 42.9 0.12 0.21 *0.11 *5.77 *Annotate: n=10, X ± SD #P<0.05 ##Compare with sham operated rats P<0.01,
* compare with model group P<0.05 * * P<0.01
Dizzy be occur the earliest in the MD symptom, modal a kind of symptom, be peripheral vertigo, be because of after membranous ampullae or the utriculus destruction, the endolymph fluid that is rich in potassium ion overflows into spatia perilymphaticum outward, make the vestibular nerve fiber produce potassium intoxication and cause (referring to Gao Yinzao, the cause of disease of Meniere, pathology and Pathophysiology, foreign medical science otolaryngology fascicle, 1984; 281), often show as sudden rotatory vertigo, the persistent period is short, but spontaneous remission and outbreak repeatedly often have vegetative nerve symptom such as nauseating, vomiting, can occur SN (referring to: Wei Xin head of a secret society compiles, hals,Nasen und Ohrenheilkunde doctor education must be read Beijing: the People's Medical Officer Press; 250,267).Dizzy is a subjective feeling, also there is not at present the directly dizzy index of reflection in the zoopery, majority shows with nystagmus, though it is dizzy that nystagmus vestibularis can not be equal to, but the nystagmus size can reflect vestibule vegetative nerve intensity to a certain extent, the excited threshold value problem of reflection vestibule, slow phase angular velocity is to represent semicircular duct function sensitive parameter, and reflection vestibule end is excitement degree slightly, thereby can reflect dizzy vestibular function state indirectly with nystagmus, dizzy degree (referring to: Shi Ming, Yu Xiangjun, Niu Haomin etc., electronystagmogram is inquired into dizzy differential diagnosis value, Hunan Medical University's journal, 1997; 22 (5): 156).
Experimental result shows: nystagmus slow phase angular velocity had obvious inhibitory action due to PAD rotated the rabbit sine, and action effect is similar with tea benzene Lamine, and prompting PAD has the effect that improves vestibule threshold of excitation, improves dizzy symptom, but did not have the H of tea benzene Lamine 1The side effect of receptor blocking agent is as drowsiness, xerostomia etc.Clinical using dosage: 3 times/day, 3 grams/time.
Embodiment 2:
Blood circulation promoting and blood stasis dispelling, the immunosuppressive action of Radix Polygalae fallacis (PAD)
1. experiment material
1.1 medicine and reagent
The preparation of PAD water extract: pulverizing medicinal materials, 10 times of water gagings soaked 12 hours, decoct after 1 hour, 8 times of reuse, 6 times of decoctings boiled 2 times each 1 hour, merged three times filtrate, were concentrated into 1: 1, got PAD water extract, and cold preservation is standby, tests used dosage in crude drug.Macromolecule right rotary glycoside (Dextran, 23.6 ten thousand units), Chinese Long March pharmaceutical factory; Heparin sodium (Heparin.Na Salt, 160,000 units), Shanghai Pujiang applied biochemistry institute, lot number: 930407; FUFANG DANSHEN ZHUSHEYE (Injectio Salvia Miltiorrhizae Composita, SMI), the Shanghai first biochemical Pharma Inc., lot number: 981224; Ethylurethanm (Urethane), chemical plant, Cao Yang second middle school, lot number: 940301; Prednisone acetate tablets (TAB.Prednisoni Acetatis, Pred), Nanjing second pharmaceutical factory, lot number: 980601; Evans indigo plant; Shanghai chemical reagent dress is purchased supply station packing factory, lot number: 910515; (Picryl Chloride, PC), the Tokyo changes into Industrial Co., Ltd to trinitro-chlorobenzene.
1.2 animal Kunming mouse 18-22g, 25-28g; SD rat 200-250g is provided by China Medicine University's new middle new drug research center Animal House;
1.3 instrument L-100 blood viscometer, scientific ﹠ technical corporation of Shanghai Medical Univ; XSP-AB microscope (band scale), optical instrument factory, the south of the River, Nanjing.
2. method and result
2.1 influence to rat blood stasis model hemorheological property due to the macromolecule right rotary glycoside
30 of SD rats, be divided into 5 groups at random, be respectively matched group, model group, positive controls, the PAD6g/kg group, the PAD3g/kg group, difference ig equivalent distilled water, ip FUFANG DANSHEN ZHUSHEYE (SMI) 4g/kg, ig PAD6,3g/kg, once-a-day, continuous 8 days, 1h after the last administration (SMI is 0.5h), ip10% urethane 1g/kg anesthesia, matched group vena femoralis injection normal saline 5ml/kg, all the other respectively organize vena femoralis injection 10% macromolecule right rotary glycoside 5ml/kg, and 20min heart blood sampling 5ml injects heparinization in vitro behind the iv, survey whole blood with the L-100 blood viscometer in 37 ℃, plasma viscosity and packed cell volume, and calculate height and cut, the low reduction ratio viscosity of cutting.By table 3-4 as seen: behind the rat iv macromolecule right rotary glycoside, whole blood contrast viscosity under the different shear rates, plasma viscosity and height are cut and are hanged down the reduction ratio viscosity of cutting and all extremely significantly increase, and obvious blood stasis phenomenon appears in the prompting rat.PAD3g/kg obviously reduces the blood stasis model rat at 80S -1-20S -1Between whole blood contrast viscosity under the different shear rates, Gao Qie and low reduction ratio viscosity of cutting are also had obvious reduction effect, plasma viscosity is had certain reduction trend.Show: PAD may improve erythrocytic morphotropism by suppressing erythrocytic gathering, thereby improves the stagnant state of the stasis of blood of blood.
Table 3, PAD are to the whole blood contrast viscosity (η that influences the different shear rates of group dosage of blood stasis rat whole blood contrast viscosity due to the macromolecule right rotary glycoside bS -1)
(g/kg) 80 60 40 30 20 contrast--7.6 ± 1.7 8.4 ± 1.9 9.3 ± 2.4 10.9 ± 6.3 12.7 ± 4.5 models--16.4 ± 3.4 ##21.9 ± 5.6 ##31.5 ± 9.1 ##42.8 ± 10.9 ##61.5 ± 15.4 ##SMI 4 9.8 ± 1.5** 11.2 ± 2.1* 13.7 ± 10.1* 18.7 ± 12.7* 30.8 ± 19.2*PAD 6 13.2 ± 4.6 17.5 ± 6.9 23.2 ± 10.2 34.2 ± 17.8 46.9 ± 12.1
3 10.8 ± 1.5*, 13.5 ± 3.4*, 16.9 ± 5.1*, 22.5 ± 7.5*, 30.8 ± 13.4* annotates: n=6, X ± SD ##* P<0.05 is compared with matched group in P<0.01, and compare with model group * * P<0.01
Table 4, PAD to blood stasis rat reduction ratio viscosity due to the macromolecule right rotary glycoside,
Plasma viscosity, packed cell volume influence group dosage reduction ratio viscosity (* 10 -2) the plasma viscosity packed cell volume
(g/kg) 20 80 (%) contrast--22.4 ± 9.4 12.6 ± 4.1 1.59 ± 0.05 53.2 ± 7.5 model--106.2 ± 27.9 ##27.1 ± 6.4 ##2.05 ± 0.25 ##57.4 ± 5.0SMI 4 51.9 ± 21.5* 15.7 ± 2.2* 1.76 ± 0.03* 53.5 ± 5.8PAD 6 84.5 ± 38.9 22.9 ± 7.7 1.82 ± 0.09 52.8 ± 8.3
Annotate 3 55.8 ± 18.8*, 18.3 ± 3.5* 1.83 ± 0.18 53.6 ± 5.9: n=6, X ± SD ##* P<0.05 is compared with matched group in P<0.01, and compare with model group * * P<0.01
2.2 PAD influences microcirculation of mouse auricle
20 of 18-22g mices, divide 4 groups at random, ip20% urethane 1.5g/kg anesthesia, cut off auricle root fine, soft fur, with microscope slide, coverslip that auricle is open and flat on microscope carrier, selection get a clear view position measure venous (V), tremulous pulse (A) diameter and intersect capillary vessel number (N) with scale, trace out simultaneously observed position and vascular morphology, so that observe once more, distinguish ig distilled water, Radix Salviae Miltiorrhizae Tabellae (SMT) 4g/kg subsequently, PAD8,4,2g/kg measure V, A diameter and N at same position behind the 1h.By table 3 as seen: PAD4g/kg, 2g/kg all have extremely significantly dilating effect to Mice Auricle fine motion, vein, the open number of blood capillary is also had extremely significantly improve, and point out PAD the microcirculatory effect that has clear improvement.
Table 5, PAD contrast after the administration before the administration after the administration before the administration after the administration microcirculatory the impact before open number (g/kg) administration of group dosage arteriole (μ m) venule (μ m) capillary of Mice Auricle--7.4 ± 1.7 7.2 ± 1.3 17.8 ± 4.5 17.2 ± 4.2 2.8 ± 2.4 2.0 ± 1.6SMT 4 7.2 ± 1.3 9.0 ± 1.5* 16.4 ± 4.1 19.2 ± 3.7* 2.4 ± 1.7 3.6 ± 1.8PAD 4 6.6 ± 1.7 8.8 ± 1.3** 16.0+4.3,19.4 ± 3.3*, 1.6 ± 0.6 3.1 ± 0.7**
2 5.8 ± 0.5 9.0 ± 1.0** 16.2+2.4,19.4 ± 2.6*, 1.2 ± 1.6 4.1 ± 1.2* annotates: n=5, and X ± SD * P<0.05, * * P<0.01 is relatively preceding with administration
2.3 PAD is to the influence of trinitro-chlorobenzene inducing mouse delayed allergy
70 of 25-30g male mice in kunming divide seven groups at random, and abdominal part is scraped hair, and 100ul is applied to mouse web portion sensitization with the 1%PC dehydrated alcohol.Induce phase: sensitization is the ig distilled water simultaneously, Pred10mg/kg, and PAD8,4g/kg, once-a-day, continuous six days; 3h is applied to the auris dextra two sides with the 1%PC olive oil and attacks after the last administration, and left ear is coated with isopyknic olive oil and compares, and surveys two ear thickness behind the 24h.Attack phase: attacked in the 6th day after the sensitization, reach behind the 16h ig distilled water respectively simultaneously, Pred10mg/kg, PAD8,4g/kg.Survey two ear thickness behind the 24h, represent delayed allergy intensity with its difference.By table 4 as seen: PAD4g/kg extremely significantly suppresses the delayed allergy of PC inducing mouse and induces phase, PAD4, and 8g/kg is remarkable, extremely significantly suppresses the delayed allergy of PC inducing mouse and attacks phase, and positive drug Pred also presents extremely significantly inhibitory action.
Table 6, PAD be phase group dosage left and right sides ear thickness difference suppression ratio during to the influencing of PC inducing mouse auricle delayed allergy
(g/kg) (×10 -2mm) (%)
Phase Pred 0.01 2.13 ± 0.64** 66.2 is induced in contrast--6.30 ± 1.06--
PAD 8 5.56±1.51 11.7
4 4.75 ± 0.75** 24.6 attacks phase Pred 0.01 1.56 ± 0.53** 75.2
PAD 8 3.50±1.08** 44.4
4 4.22±0.97* 33.0
Annotate: n=10, X ± SD * P<0.05, * * P<0.01 is with matched group relatively
Macromolecule right rotary glycoside can cause that erythrocyte aggregation increases, and adds the high viscosity of itself, easily causes stasis syndrome [7]Behind the rat intravenous injection macromolecule right rotary glycoside, 20 ~ 80S -1Each shear rate whole blood contrast viscosity and plasma viscosity all significantly increase, and high shear rate mainly reflects red cell deformability, and low shear rate mainly reflects erythrocyte aggregation, and this experimental result shows: PAD has remarkable reduction height to cut (80S -1) T and the low (20S that cuts -1) whole blood contrast viscosity and reduction ratio viscosity thereof, plasma viscosity there is certain reduction trend.In addition, PAD has remarkable dilating effect to the Mice Auricle blood capillary, and obviously increases the open number of blood capillary.Show that PAD can reduce erythrocyte aggregation, increase erythrocytic morphotropism, blood viscosity lowering, expansion blood capillary, microcirculation improvement.Show that PAD has obvious function of promoting blood circulation to disperse blood clots.
PAD xylol induced mice auricle edema and inflammatory mediator histamine cause that the increase of mouse skin capillary permeability all has remarkable inhibitory action, and PC inducing mouse IV allergy-induced is all had remarkable inhibitory action mutually with attacking mutually.Prompting: but PAD both inflammation-inhibiting medium or inflammatory reaction cause the penetrating increase of blood vessel, can suppress the immune inflammation process again.Show that PAD has obvious immune antiinflammatory action.
The above-mentioned Radix Polygalae fallacis (PAD) that experimental results show that has blood circulation promoting and blood stasis dispelling, immunity, antiinflammatory action.

Claims (10)

1, the application of Radix Polygalae fallacis in preparation treatment Meniere medicine.
2, according to the application of the described Radix Polygalae fallacis of claim 1 in preparation treatment Meniere medicine, it is characterized in that: the decocting liquid that uses Radix Polygalae fallacis.
3, according to the application of the described Radix Polygalae fallacis of claim 2 in preparation treatment Meniere medicine, it is characterized in that: the water soluble ingredient that uses Radix Polygalae fallacis.
4, according to the application of the described Radix Polygalae fallacis of claim 1~3 in preparation treatment Meniere medicine, it is characterized in that: the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis, can mix with conventional pharmaceutic adjuvant.
5, according to the application of the described Radix Polygalae fallacis of claim 4 in preparation treatment Meniere medicine, it is characterized in that: the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis after pharmaceutic adjuvant mixes, can be made into various preparations.
6, the application of Radix Polygalae fallacis in the preparation activating blood and removing stasis drug.
7, according to the application of the described Radix Polygalae fallacis of claim 6 in the preparation activating blood and removing stasis drug, it is characterized in that: the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis, can mix with pharmaceutic adjuvant.
8, the application of Radix Polygalae fallacis in the preparation immune drug.
9, the application of described according to Claim 8 Radix Polygalae fallacis in the preparation immune drug is characterized in that: the decocting liquid or the water soluble ingredient of Radix Polygalae fallacis, can mix with pharmaceutic adjuvant.
10, the application of Radix Polygalae fallacis in the preparation anti-inflammatory drug.
CN 02112749 2002-03-12 2002-03-12 Application of yellowstem milkwort in preparing medicines Expired - Fee Related CN1209127C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 02112749 CN1209127C (en) 2002-03-12 2002-03-12 Application of yellowstem milkwort in preparing medicines

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 02112749 CN1209127C (en) 2002-03-12 2002-03-12 Application of yellowstem milkwort in preparing medicines

Publications (2)

Publication Number Publication Date
CN1382476A true CN1382476A (en) 2002-12-04
CN1209127C CN1209127C (en) 2005-07-06

Family

ID=4742223

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 02112749 Expired - Fee Related CN1209127C (en) 2002-03-12 2002-03-12 Application of yellowstem milkwort in preparing medicines

Country Status (1)

Country Link
CN (1) CN1209127C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102824458A (en) * 2012-07-28 2012-12-19 陈双玲 Traditional Chinese medicine for qi deficiency and blood stasis type dysmenorrhea
CN102973707A (en) * 2012-11-23 2013-03-20 王恩瀚 Drug composite for treating infantile eczema and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102824458A (en) * 2012-07-28 2012-12-19 陈双玲 Traditional Chinese medicine for qi deficiency and blood stasis type dysmenorrhea
CN102973707A (en) * 2012-11-23 2013-03-20 王恩瀚 Drug composite for treating infantile eczema and preparation method thereof

Also Published As

Publication number Publication date
CN1209127C (en) 2005-07-06

Similar Documents

Publication Publication Date Title
CN1228071C (en) Medicament for treating cervical spondylosis and preparation method thereof
CN100450518C (en) Ready prepared Chinese medicine for treating epicophosis and sonitus
CN101402661A (en) Uses of iridoid glycoside compounds in preparing hemostatic and pain easing medicament
CN1209127C (en) Application of yellowstem milkwort in preparing medicines
CN1112424A (en) Toutongning-medicine for headache
CN1839986A (en) Method for extracting effective site of Xanthoceras sorbifolia hulled seed
JP2020528926A (en) A pharmaceutical composition containing an avocado oil fraction as an active ingredient for the prevention or treatment of hearing loss.
CN1293910C (en) Compound gastrodin injection and its preparation and use
CN113101339B (en) Decoction for treating chronic liver injury and preparation method and application thereof
CN102552715B (en) Chinese medicinal composition, medicine containing Chinese medicinal composition and preparation method of medicine
RU2317805C2 (en) Method for treating acute posttraumatic cephalgia cases
CN103211982A (en) Medicament for treating prosopalgia
CN102240357B (en) Medicament for treating tinnitus and preparation method thereof
CN1285363C (en) Chinese and western compound medicinal eye drop for quick treatment of eyeball congestion disease
TWI404542B (en) Compositions of clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits
CN1068790C (en) Medicinal composition containing total saponin extracted from stem and leaves of American ginseng
CN101829132B (en) Application of 7-O-beta-D-acetylation sugar-coumarin compounds in treating chronic neuropathic pains
CN101450063A (en) Oral medicine for treating hypochondria
CN1265802C (en) Effective extract of Chinese silkuine bark with cardotonic function and its preparing process and uasge
CN1415303A (en) Red sage root and Tienchi sustained release medication, its preparation method and medicinal application in vascular dementia
CN101264312A (en) Medicaments for treating dizziness
CN1210016A (en) Anti-cigarette health-care products
RU2589260C1 (en) Pletnev drops possessing coagulating agent action, and method of treating thrombocytopenia in hepatic diseases and leukaemia
CN101837000B (en) Application of 2-fluroin-beta-D-glycoside in treating neuropathic pain
CN1522723A (en) Novel use of traditional Chinese medicine rabdosia rubeseens and Isodon longitubus

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee